Skip to main content
Figure 2 | Molecular Cancer

Figure 2

From: Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib

Figure 2

Effect of NVP-BEZ235 alone or combined with Sorafenib on renal cancer cell proliferation. A, 786-0 cells were treated with NVP-BEZ235 (NVP; 1 μM) alone or combined to Sorafenib (Soraf; 10 μM). Cells were counted after 48 or 72 hours of treatment as described under Materials and Methods. Columns, mean cell count of three independent experiments; bars, SD. B, BrdU uptake of 786-0 cells treated with NVP-BEZ235 (NVP, 1 μM) or Sorafenib (Soraf, 10 μM) either alone or in combination, or DMSO (Control), for 24 hours. Results are quantified as percentage of positive 786-0 cells for BrdU incorporation. Columns, mean percentage of three independent experiments; bars, SD. C, samples processed and analyzed under a fluorescence microscope. (Magnification 100×. Scale bar 100 μm). *, P < 0.05, #, P < 0.001 compared to control, or otherwise as specified by brackets.

Back to article page

Molecular Cancer

ISSN: 1476-4598